- Home
- QURE vs LNSR Comparison
QURE vs LNSR Comparison
Compare QURE & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- LNSR
- Stock Information
- Founded
- QURE 1998
- LNSR 2004
- Country
- QURE Netherlands
- LNSR United States
- Employees
- QURE N/A
- LNSR N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- LNSR Medical Electronics
- Sector
- QURE Health Care
- LNSR Health Care
- Exchange
- QURE Nasdaq
- LNSR Nasdaq
- Market Cap
- QURE 4.3B
- LNSR 142.0M
- IPO Year
- QURE 2007
- LNSR N/A
- Fundamental
- Price
- QURE $67.69
- LNSR $12.30
- Analyst Decision
- QURE Strong Buy
- LNSR Hold
- Analyst Count
- QURE 12
- LNSR 1
- Target Price
- QURE $69.67
- LNSR $15.00
- AVG Volume (30 Days)
- QURE 2.3M
- LNSR 45.9K
- Earning Date
- QURE 10-29-2025
- LNSR 11-06-2025
- Dividend Yield
- QURE N/A
- LNSR N/A
- EPS Growth
- QURE N/A
- LNSR N/A
- EPS
- QURE N/A
- LNSR N/A
- Revenue
- QURE $14,337,000.00
- LNSR $58,364,000.00
- Revenue This Year
- QURE N/A
- LNSR $30.80
- Revenue Next Year
- QURE $229.18
- LNSR $33.09
- P/E Ratio
- QURE N/A
- LNSR N/A
- Revenue Growth
- QURE N/A
- LNSR 29.34
- 52 Week Low
- QURE $5.35
- LNSR $5.28
- 52 Week High
- QURE $71.50
- LNSR $17.31
- Technical
- Relative Strength Index (RSI)
- QURE 66.33
- LNSR 55.62
- Support Level
- QURE $58.05
- LNSR $11.85
- Resistance Level
- QURE $71.50
- LNSR $12.09
- Average True Range (ATR)
- QURE 3.84
- LNSR 0.25
- MACD
- QURE -0.68
- LNSR 0.03
- Stochastic Oscillator
- QURE 72.51
- LNSR 87.90
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About LNSR LENSAR Inc.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.